|
KMID : 0383820110710030210
|
|
Tuberculosis and Respiratory Diseases
2011 Volume.71 No. 3 p.210 ~ p.215
|
|
|
Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients
|
|
Kim Tae-Hoon
Kim Byung-Gyu
Cho Sung-Woo
Cho Sung-Kyun
Yuh Young-Jin
Kim Sung-Rok
Kim Hyun-Jung
|
|
|
Abstract
|
|
|
|
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.
|
|
|
KEYWORD
|
|
|
imatinib mesylate, Lung Diseases, Interstitial, Chronic Myeloid Leukemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|